Chun TW, Davey RT Jr, Engel D, Lane HC, Fauci AS. Re-emergence of HIV after stopping therapy [In Process Citation]. Nature. 1999;401:874–5.

Article  CAS  PubMed  Google Scholar 

Eisele E, Siliciano RF. Redefining the viral reservoirs that prevent HIV-1 eradication. Immunity. 2012;37:377–88.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lorenzo-Redondo R, Fryer HR, Bedford T, Kim E-Y, Archer J, Kosakovsky Pond SL, et al. Persistent HIV-1 replication maintains the tissue reservoir during therapy. Nature. 2016;530:51–6.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bozzi G, Simonetti FR, Watters SA, Anderson EM, Gouzoulis M, Kearney MF, et al. No evidence of ongoing HIV replication or compartmentalization in tissues during combination antiretroviral therapy: Implications for HIV eradication. Sci Adv. 2019;5:eaav2045.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chaillon A, Gianella S, Dellicour S, Rawlings SA, Schlub TE, De Oliveira MF, et al. HIV persists throughout deep tissues with repopulation from multiple anatomical sources. J Clin Investig. 2020;130:1699–712.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wu Y, Beddall MH, Marsh JW. Rev-dependent lentiviral expression vector. Retrovirology. 2007;4:12.

Article  PubMed  PubMed Central  Google Scholar 

Young J, Tang Z, Yu Q, Yu D, Wu Y. Selective killing of HIV-1-positive macrophages and T Cells by the Rev-dependent lentivirus carrying anthrolysin O from Bacillus anthracis. Retrovirology. 2008;5:36.

Article  PubMed  PubMed Central  Google Scholar 

Wang Z, Tang Z, Zheng Y, Yu D, Spear M, Iyer SR, et al. Development of a nonintegrating Rev-dependent lentiviral vector carrying diphtheria toxin A chain and human TRAF6 to target HIV reservoirs. Gene Ther. 2010;17:1063–76.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Malim MH, Hauber J, Le SY, Maizel JV, Cullen BR. The HIV-1 rev trans-activator acts through a structured target sequence to activate nuclear export of unspliced viral mRNA. Nature. 1989;338:254–7.

Article  CAS  PubMed  Google Scholar 

Shingai M, Donau OK, Plishka RJ, Buckler-White A, Mascola JR, Nabel GJ, et al. Passive transfer of modest titers of potent and broadly neutralizing anti-HIV monoclonal antibodies block SHIV infection in macaques. J Exp Med. 2014;211:2061–74.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Liu J, Ghneim K, Sok D, Bosche WJ, Li Y, Chipriano E, et al. Antibody-mediated protection against SHIV challenge includes systemic clearance of distal virus. Science. 2016;353:1045–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Nishimura Y, Gautam R, Chun T-W, Sadjadpour R, Foulds KE, Shingai M, et al. Early antibody therapy can induce long-lasting immunity to SHIV. Nature. 2017;543:559–63.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Halper-Stromberg A, Lu C-L, Klein F, Horwitz JoshuaA, Bournazos S, Nogueira L, et al. Broadly Neutralizing Antibodies and Viral Inducers Decrease Rebound from HIV-1 Latent Reservoirs in Humanized Mice. Cell. 2014;158:989–99.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Caskey M, Klein F, Lorenzi JCC, Seaman MS, West AP, Buckley N, et al. Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117. Nature. 2015;522:487–91.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bar KJ, Sneller MC, Harrison LJ, Justement JS, Overton ET, Petrone ME, et al. Effect of HIV Antibody VRC01 on Viral Rebound after Treatment Interruption. N Engl J Med. 2016;375:2037–50.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ostertag W, Roesler G, Krieg CJ, Kind J, Cole T, Crozier T, et al. Induction of endogenous virus and of thymidine kinase by bromodeoxyuridine in cell cultures transformed by Friend virus. Proc Natl Acad Sci USA. 1974;71:4980–5.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yarchoan R, Weinhold K, Lyerly HK, Gelmann E, Blum R, Shearer G, et al. Administration Of 3’-Azido-3’-Deoxythymidine, An Inhibitor Of Htlv-Iii/Lav Replication, To Patients With Aids Or Aids-Related Complex. Lancet. 1986;327:575–80.

Article  Google Scholar 

Finzi D, Blankson J, Siliciano JD, Margolick JB, Chadwick K, Pierson T, et al. Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat Med. 1999;5:512–7.

Article  CAS  PubMed  Google Scholar 

Montessori V, Press N, Harris M, Akagi L, Montaner JS. Adverse effects of antiretroviral therapy for HIV infection. CMAJ. 2004;170:229–38.

PubMed  PubMed Central  Google Scholar 

Siliciano RF. Reservoirs for HIV-1. Curr Infect Dis Rep. 1999;1:298–304.

Article  CAS  PubMed  Google Scholar 

Tang Y, Chaillon A, Gianella S, Wong LM, Li D, Simermeyer TL, et al. Brain microglia serve as a persistent HIV reservoir despite durable antiretroviral therapy. J Clin Investig. 2023;133:e167417.

Article  PubMed  PubMed Central  Google Scholar 

Rodari A, Darcis G, Lint CMV. The Current Status of Latency Reversing Agents for HIV-1 Remission. Annu Rev Virol. 2021;8:491–514.

Article  CAS  PubMed  Google Scholar 

Hayashi T, Jean M, Huang H, Simpson S, Santoso NG, Zhu J. Screening of an FDA-approved compound library identifies levosimendan as a novel anti-HIV-1 agent that inhibits viral transcription. Antivir Res. 2017;146:76–85.

Article  CAS  PubMed  Google Scholar 

Li Z, Hajian C, Greene WC. Identification of unrecognized host factors promoting HIV-1 latency. PLOS Pathog. 2020;16:e1009055.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Archin NM, Liberty AL, Kashuba AD, Choudhary SK, Kuruc JD, Crooks AM, et al. Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature. 2012;487:482–5.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Martinez-Navio JM, Fuchs SP, Pantry SN, Lauer WA, Duggan NN, Keele BF, et al. Adeno-Associated Virus Delivery of Anti-HIV Monoclonal Antibodies Can Drive Long-Term Virologic Suppression. Immunity. 2019;50:567–75.e5.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wu Y, Beddall MH, Marsh JW. Rev-dependent indicator T cell line. Curr HIV Res. 2007;5:395–403.

Google Scholar 

Berkhout B, Jeang KT. trans activation of human immunodeficiency virus type 1 is sequence specific for both the single-stranded bulge and loop of the trans-acting-responsive hairpin: a quantitative analysis. J Virol. 1989;63:5501–4.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zapp ML, Green MR. Sequence-specific RNA binding by the HIV-1 Rev protein. Nature. 1989;342:714–6.

Article  CAS  PubMed